RxDoctor Payments Data

Albert Ferrara, DO

Internal Medicine · East Meadow, NYNPI 1205940434

Payments from drug & device makers

$8,422in general payments, 2019–2025

Across 458 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$1K
  • AbbVie$926
  • Lilly USA, LLC$537
  • Pfizer$441
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$8,422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,422 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$541,860
Medicare patients
818
Services billed
9,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$157,934
EliquisApixaban63$81,989
MounjaroTirzepatide53$76,475
FarxigaDapagliflozin Propanediol43$54,649
XareltoRivaroxaban50$47,442
JardianceEmpagliflozin27$36,106
JanuviaSitagliptin Phosphate22$30,909
TrulicityDulaglutide22$22,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,006
Tresiba Flextouch U-100Insulin Degludec14$7,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,886
Duloxetine Hcl137$5,210
SynthroidLevothyroxine Sodium60$4,474
Atorvastatin Calcium443$4,390
Rosuvastatin Calcium372$4,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,133$157,934129 claims
Lilly USA, LLCMounjaro, Trulicity$537$99,47175 claims
PfizerEliquis$441$81,98963 claims
AstraZenecaFarxiga$1,087$54,64943 claims
Johnson & JohnsonXarelto$149$47,44250 claims
Boehringer IngelheimJardiance$160$36,10627 claims
MerckJanuvia$250$30,90922 claims
GSKTrelegy Ellipta$1,076$21,00624 claims
AbbVieSynthroid$926$4,47460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →